HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer

Rezultati

Naziv:	HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer
Autori:	Maglakelidze, Marina; Ryspayeva, D; Andric, Zoran G ; Petrovic, Zeljko M; Bulat, IV; Nikolic, Ivan V ; Chawla, T; Nagarkar, R; Wiedermann, Ursula; Blumenstein, BA; Chong, LMO; Ede, NJ; Nixon, B; Good, AJ;
Godina:	2022
Publikacija:	ANNALS OF ONCOLOGY
ISSN:	0923-7534 Annals of Oncology Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 33 br. Suppl 9 str. S1460-S1460
DOI:	10.1016/j.annonc.2022.10.110
WoS-ID:	000897943700076
URI:	https://enauka.gov.rs/handle/123456789/828156
Projekat:	Imugene Limited
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
Napomena:	ESMO Asia Congress, Singapore, SINGAPORE, DEC 02-04, 2022
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Alt metrika

Dimensions

Unpaywall

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.